These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Identification of a novel anti-EGFR nanobody by phage display and its distinct paratope and epitope via homology modeling and molecular docking. Xi X; Sun W; Su H; Zhang X; Sun F Mol Immunol; 2020 Dec; 128():165-174. PubMed ID: 33130376 [TBL] [Abstract][Full Text] [Related]
6. Conversion of a murine monoclonal antibody A13 targeting epidermal growth factor receptor to a human monoclonal antibody by guided selection. Chang KH; Kim MS; Hong GW; Shin YN; Kim SH Exp Mol Med; 2012 Jan; 44(1):52-9. PubMed ID: 22064379 [TBL] [Abstract][Full Text] [Related]
7. Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody". Sharifi J; Khirehgesh MR; Akbari B; Soleymani B; Mansouri K Mol Biotechnol; 2021 Jun; 63(6):525-533. PubMed ID: 33772436 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy. Bedi A; Chang X; Noonan K; Pham V; Bedi R; Fertig EJ; Considine M; Califano JA; Borrello I; Chung CH; Sidransky D; Ravi R Mol Cancer Ther; 2012 Nov; 11(11):2429-39. PubMed ID: 22927667 [TBL] [Abstract][Full Text] [Related]
9. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. Oliveira S; Schiffelers RM; van der Veeken J; van der Meel R; Vongpromek R; van Bergen En Henegouwen PM; Storm G; Roovers RC J Control Release; 2010 Jul; 145(2):165-75. PubMed ID: 20362020 [TBL] [Abstract][Full Text] [Related]
10. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab. Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124 [TBL] [Abstract][Full Text] [Related]
11. A bispecific nanobody targeting the dimerization interface of epidermal growth factor receptor: Evidence for tumor suppressive actions in vitro and in vivo. Xu Z; Qiu C; Wen B; Wang S; Zhu L; Zhao L; Li H Biochem Biophys Res Commun; 2021 Apr; 548():78-83. PubMed ID: 33636638 [TBL] [Abstract][Full Text] [Related]
15. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Tijink BM; Laeremans T; Budde M; Stigter-van Walsum M; Dreier T; de Haard HJ; Leemans CR; van Dongen GA Mol Cancer Ther; 2008 Aug; 7(8):2288-97. PubMed ID: 18723476 [TBL] [Abstract][Full Text] [Related]
16. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Garrido G; Tikhomirov IA; Rabasa A; Yang E; Gracia E; Iznaga N; Fernández LE; Crombet T; Kerbel RS; Pérez R Cancer Biol Ther; 2011 Feb; 11(4):373-82. PubMed ID: 21150278 [TBL] [Abstract][Full Text] [Related]
17. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688 [TBL] [Abstract][Full Text] [Related]
18. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. Emanuel SL; Engle LJ; Chao G; Zhu RR; Cao C; Lin Z; Yamniuk AP; Hosbach J; Brown J; Fitzpatrick E; Gokemeijer J; Morin P; Morse BA; Carvajal IM; Fabrizio D; Wright MC; Das Gupta R; Gosselin M; Cataldo D; Ryseck RP; Doyle ML; Wong TW; Camphausen RT; Cload ST; Marsh HN; Gottardis MM; Furfine ES MAbs; 2011; 3(1):38-48. PubMed ID: 21099371 [TBL] [Abstract][Full Text] [Related]
20. A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan. Qiu W; Zhang C; Wang S; Yu X; Wang Q; Zeng D; Du P; Ma J; Zheng Y; Pang B; Yu Y; Long F; Pang X; Sun Z J Immunol Res; 2019; 2019():3017360. PubMed ID: 30733972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]